Giuseppe Banna, Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared a post on LinkedIn:
“I was truly honoured to deliver my talk, ‘Emerging ADCs: The Next Generation,’ at the WCLC2025 Education Session: ADCs – Current Controversies.
In my presentation, I discussed how we should move beyond the traditional view of ADCs as ‘smart chemotherapy drugs’ and instead embrace them as modular platforms. This perspective enables us to strategically optimise each component, including targets, payloads, linkers, and antibodies, to address tumour biology more comprehensively.
Key areas include:
- Expanding targets beyond cell-surface antigens to encompass tumour microenvironment and metabolic dependencies.
- Harnessing immune-stimulating ADCs (ISACs) as a novel therapeutic class.
- Exploring innovative payloads such as protein degraders and oligonucleotides.
- Leveraging smart engineering for bispecific and dual-payload ADCs to overcome resistance.
- Designing rational combinations with targeted therapies.
- Ensuring smarter, more efficient translation from early-phase studies into later development, potentially accelerated by quantum systems applications.
- Prioritising biomarker-driven stratification for optimal clinical benefit.
It was a great pleasure to share this session with fantastic colleagues: Riyaz Shah, Fiona McDonald, Sewanti Limaye, Susan Scott, Stephanie Saw
A special thanks to the IASLC Scientific Committee for the kind invitation, and in particular to Jarushka Naidoo and Umberto Malapelle.
Congratulations on organising an extraordinary WCLC2025!”
